Cost effectiveness of treatments for stroke prevention in atrial fibrillation: focus on the novel oral anticoagulants
C Kasmeridis, S Apostolakis, L Ehlers… - …, 2013 - Springer
For more than 5 decades, the only available treatment for the prevention of atrial fibrillation
(AF)-related stroke were the vitamin K antagonists. Recently, novel oral anticoagulants …
(AF)-related stroke were the vitamin K antagonists. Recently, novel oral anticoagulants …
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
A Janzic, M Kos - Pharmacoeconomics, 2015 - Springer
Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and …
S Deitelzweig, A Amin, Y Jing… - Journal of medical …, 2012 - Taylor & Francis
Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review
NL Liberato, M Marchetti - Expert Review of Pharmacoeconomics …, 2016 - Taylor & Francis
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) into clinical
practice represented a major change in the treatment of non-valvular atrial fibrillation …
practice represented a major change in the treatment of non-valvular atrial fibrillation …
Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US
B von Schéele, M Fernandez… - Annals of …, 2013 - journals.sagepub.com
OBJECTIVE To summarize the available evidence on the issues in health economics related
to oral anticoagulation for stroke prevention in atrial fibrillation (AF) in the US. DATA …
to oral anticoagulation for stroke prevention in atrial fibrillation (AF) in the US. DATA …
[HTML][HTML] Novel anticoagulants for stroke prevention in atrial fibrillation: a systematic review of cost-effectiveness models
BL Limone, WL Baker, J Kluger, CI Coleman - PloS one, 2013 - journals.plos.org
Objective To conduct a systematic review of economic models of newer anticoagulants for
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …
stroke prevention in atrial fibrillation (SPAF). Patients and Methods We searched Medline …
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation
AR Kansal, Y Zheng, T Pokora, SV Sorensen - Best Practice & Research …, 2013 - Elsevier
Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …
high human and economic burden. Novel oral anticoagulants have been approved in many …
Methods for economic evaluations of novel oral anticoagulants in patients with atrial fibrillation: a systematic review
Y Li, P Chen, X Wang, Q Peng, S Xu, A Ma… - Applied Health Economics …, 2024 - Springer
Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …
among the elderly population worldwide, with substantial economic and social burdens …
Cost-effectiveness of novel oral anticoagulants for stroke prevention in non-valvular atrial fibrillation
SM Singh, HC Wijeysundera - Current cardiology reports, 2015 - Springer
Recently, novel oral anticoagulants (NOACs) have been approved for stroke prevention in
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
patients with atrial fibrillation (AF). Although these agents overcome some disadvantages of …
Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation
PSJ Miller, MF Drummond, LK Langkilde… - European heart …, 2005 - academic.oup.com
Our objective is to summarize the key components of a health economic evaluation of
antithrombotic treatments for stroke prevention in patients with atrial fibrillation (AF). The key …
antithrombotic treatments for stroke prevention in patients with atrial fibrillation (AF). The key …
相关搜索
- cost effectiveness stroke prevention
- atrial fibrillation stroke prevention
- cost effectiveness atrial fibrillation
- antithrombotic treatments stroke prevention
- anticoagulant therapy stroke prevention
- cost effectiveness anticoagulant therapy
- antithrombotic treatments atrial fibrillation
- atrial fibrillation anticoagulant therapy
- economic factors stroke prevention
- atrial fibrillation economic evaluations
- cost reductions fibrillation patients
- cost effectiveness stroke in patients
- atrial fibrillation stroke in patients
- atrial fibrillation economic factors